USPTO serial 90572014
AURORA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Feb 8, 2022
- Examiner
- HUSSAIN, TASNEEM
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with AURORA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Abingdon, Oxfordshire, GB
Abingdon, Oxfordshire, GB
Abingdon, Oxfordshire, GB
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Andrew D. Price
ANDREW D. PRICE VENABLE LLPP.O. BOX 34385WASHINGTON, DC 20043-9998UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment of cancer, viral infections, autoimmune diseases, and tumorous diseases, excluding ophthalmic pharmaceutical preparations; biological preparations for the treatment of viral infections; biological preparations for the treatment of autoimmune diseases; biological preparations for medical use for the treatment of tumorous diseases; immunotherapeutic drugs, namely, pharmaceutical preparations for the treatment of cancer, viral infections, autoimmune diseases, tumorous diseases; reagents for medical use; diagnostic preparations for medical purposes; diagnostic reagents for medical use; medical diagnostic reagents used in connection with drug discovery, namely, the identification of pharmaceutical targets and the development of molecules to be used for medicinal or therapeutic purposes; medical diagnostic reagents used in connection with protein engineering and biological drug development | ACTIVE | — |
| 042 | Scientific and technological services, namely, pharmaceutical research and design relating thereto; pharmaceutical research and development services; pharmaceutical testing and clinical trials; research and development in the biotechnology field; drug discovery, namely, the identification of pharmaceutical targets and the development of molecules to be used for medicinal or therapeutic purposes; protein engineering and biological drug development; provision of information and consultancy in relation to the aforesaid services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Immunocore Limited
- Other trademarks owned by Immunocore Limited
- Other trademarks owned by Immunocore Limited
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named AURORA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 20, 2024 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Dec 28, 2022 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Feb 8, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 30, 2021 | ISPO | WITHDRAWN FROM ISSUE - PETITIONS OFFICE REQUEST | — |
| Nov 24, 2021 | D1BR | TEAS DELETE 1(B) BASIS RECEIVED | — |
| Nov 23, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 23, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 3, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 19, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 6, 2021 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Oct 6, 2021 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Oct 6, 2021 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Oct 6, 2021 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Oct 4, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 24, 2021 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Jun 17, 2021 | ALIE | ASSIGNED TO LIE | — |
| Jun 10, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 29, 2021 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Mar 13, 2021 | NWAP | NEW APPLICATION ENTERED | — |